Cargando…
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi‐country observational study
INTRODUCTION: Clinical guidelines recommend extended treatment with dual antiplatelet therapy (DAPT) with ticagrelor 60 mg (twice daily) beyond 12 months in high‐risk patients with a history of myocardial infarction (MI) who have previously tolerated DAPT and are not at heightened bleeding risk. How...
Autores principales: | Lesén, Eva, Hewitt, Christopher, Giannitsis, Evangelos, Hedberg, Jonatan, Jernberg, Tomas, Lambrelli, Dimitra, Maggioni, Aldo P., Simeone, Jason C., Ariza‐Solé, Albert, Storey, Robert F., ten Berg, Jurrien, Bonaca, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495086/ https://www.ncbi.nlm.nih.gov/pubmed/34365644 http://dx.doi.org/10.1002/clc.23702 |
Ejemplares similares
-
Aletheia.
Publicado: (1982) -
Alétheia : la verdad originaria : encubrimiento y desencubrimiento del ser en Martin Heidegger /
por: Rivero Weber, Paulina
Publicado: (2004) -
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019) -
Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013) -
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)